RxDoctor Payments Data

William Wnuk, MD

Internal Medicine · Springville, NYNPI 1528069085

Payments from drug & device makers

$1,766in general payments, 2019–2025

Across 99 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$403
  • AbbVie$387
  • Lilly USA, LLC$156
  • Novo Nordisk$117
  • Amgen$90
  • Edwards Lifesciences$73
  • plus $540 from 16 others

What the payments were for

  • Food & beverage$1,75299%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,766 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$15,908
Medicare patients
99
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$168,517
XareltoRivaroxaban51$58,235
JardianceEmpagliflozin52$57,847
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$33,276
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$24,784
FarxigaDapagliflozin Propanediol22$24,769
TradjentaLinagliptin22$23,945
MounjaroTirzepatide19$19,312
JanuviaSitagliptin Phosphate23$17,853
TrulicityDulaglutide12$13,492
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$12,094
Breo ElliptaFluticasone/Vilanterol20$9,807
Metoprolol Succinate490$8,711
Levothyroxine Sodium582$8,514
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$8,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$168,517197 claims
Boehringer IngelheimJardiance, Tradjenta$63$81,79274 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$403$61,22599 claims
Lilly USA, LLCMounjaro, Trulicity$156$32,80431 claims
MerckJanuvia$47$17,85323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Springville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →